Interpace Biosciences, Inc. (IDXG)

Market Cap	3.80M
Revenue (ttm)	48.26M
Net Income (ttm)	7.18M
Shares Out	4.42M
EPS (ttm)	0.33
PE Ratio	2.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,400
Average Volume	5,332
Open	0.9650
Previous Close	0.9650
Day's Range	0.8601 - 1.0700
52-Week Range	0.4433 - 3.5400
Beta	0.71
RSI	56.46
Earnings Date	Aug 11, 2025

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy ri...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 111
• Stock Exchange: OTCMKTS
• Ticker Symbol: IDXG

Financial Performance

In 2024, Interpace Biosciences's revenue was $46.93 million, an increase of 17.21% compared to the previous year's $40.04 million. Earnings were $6.24 million, an increase of 219.24%.